Liminatus Pharma, Inc. — Form 8-K
Filed September 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Liminatus Pharma regained compliance with Nasdaq's minimum bid price rule on September 24, 2026, after the closing bid price exceeded $1.00 for 13 consecutive trading days (August 21–September 9, 2026). The company had fallen below the $1.00 threshold in January 2026, was transferred to Nasdaq Capital Market on August 4, 2026, and executed a 1-for-50 reverse stock split on August 20, 2026 to meet the requirement. No financial impact, capital raise, or operational changes are disclosed.
Why this rating
Compliance restoration is necessary but routine for public companies; no business operations, revenue, or strategic change. Stock price stabilization is administrative, not transformational relative to $221M market cap.
See more from September 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.